Yahoo Web Search

Search results

  1. Jun 28, 2024 · BioMarin develops and markets medicines for life-threatening genetic conditions, such as achondroplasia, hemophilia A, and PKU. Learn about their breakthrough science, patient focus, and people-first culture.

    • Careers

      BioMarin Pharmaceutical does not accept unsolicited resumes...

    • Investor Relations

      At Biomarin Pharmaceutical Inc., we promise to treat your...

    • Contact Us

      BioMarin RareConnections™ Tel: +1 (866) 906-6100 Fax: +1...

    • Pipeline

      Our pipeline includes investigational medicines across four...

    • Leadership Team

      BioMarin Leadership Team. Alexander Hardy. President and...

    • Our Science

      At BioMarin, we’re committed to delivering on the promise of...

    • Our Treatments

      Products and Pipeline. For more than two decades, we have...

    • Our Company

      BioMarin is a global biotechnology company that relentlessly...

  2. BioMarin develops and commercializes medicines for rare and inherited conditions, using enzyme replacement, gene therapy and other modalities. Founded in 1997, BioMarin has eight approved products and a diverse pipeline of candidates.

  3. BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research is in enzyme replacement therapies (ERTs).

  4. BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.

  5. BioMarin is a biopharmaceutical company that develops and commercializes therapies for rare diseases based on genetic insights. Learn about its eight approved products and its robust pipeline of clinical-stage and preclinical programs.

  6. BioMarin Pharmaceutical Inc. | 167,380 followers on LinkedIn. We transform lives through genetic discovery. | Founded in 1997, BioMarin is a global biotechnology company dedicated to...

  7. Aug 24, 2022 · Maintains Orphan Drug Designation (ODD) in the EU Providing 10-years of Market Exclusivity. Significant Benefit Over Existing Therapies for Patients with Severe Hemophilia A in EU Based on EMA Determination of ODD. Conference Call and Webcast to be Held Wed., Aug. 24th at 8:00 pm Eastern.

  1. Searches related to BioMarin Pharmaceutical

    BioMarin Pharmaceutical inc